These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 22161953)
1. Can objective endpoints be manipulated in unmasked trials? Berger VW Stat Med; 2011 Dec; 30(30):3573-4; author reply 3575. PubMed ID: 22161953 [No Abstract] [Full Text] [Related]
2. Show drugs work before selling them. Sipp D; McCabe C; Rasko JE Nature; 2017 Mar; 543(7644):174-175. PubMed ID: 28277530 [No Abstract] [Full Text] [Related]
3. Regulatory watch: FDA new drug approvals in Q2 2018. Urquhart L Nat Rev Drug Discov; 2018 Jul; 17(8):536-537. PubMed ID: 30057412 [No Abstract] [Full Text] [Related]
4. FDA reveals new initiatives to deal with drug shortages. McCarthy M BMJ; 2013 Nov; 347():f6646. PubMed ID: 24188905 [No Abstract] [Full Text] [Related]
5. Combination products regulation at the FDA. Lauritsen KJ; Nguyen T Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151 [TBL] [Abstract][Full Text] [Related]
6. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health. Gostin LO JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642 [No Abstract] [Full Text] [Related]
7. Accelerated approvals under the microscope. Mullard A Nat Rev Drug Discov; 2021 Jun; 20(6):409-411. PubMed ID: 34012001 [No Abstract] [Full Text] [Related]
9. Microdosing Studies in Children: A US Regulatory Perspective. Roth-Cline M; Nelson RM Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312 [TBL] [Abstract][Full Text] [Related]
10. Pharmaceuticals and medical devices: FDA oversight. ; Berry MD Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845 [No Abstract] [Full Text] [Related]
11. The right to a trial: Should dying patients have access to experimental drugs? Groopman J New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539 [No Abstract] [Full Text] [Related]
12. The history and contemporary challenges of the US Food and Drug Administration. Borchers AT; Hagie F; Keen CL; Gershwin ME Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043 [TBL] [Abstract][Full Text] [Related]
13. The regulation of drugs and biologics: fifty years into the future. Kuhlik BN Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358 [No Abstract] [Full Text] [Related]
14. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy. Sinha V; Zhao P; Huang SM; Zineh I Clin Pharmacol Ther; 2014 May; 95(5):478-80. PubMed ID: 24747236 [TBL] [Abstract][Full Text] [Related]
15. Why Collecting Pharmacokinetic Information After Intravenous Drug Administration Is Important. Hinderling PH; Papoian T Clin Pharmacol Drug Dev; 2020 Feb; 9(2):146-150. PubMed ID: 31943891 [No Abstract] [Full Text] [Related]
16. Safe drugs and the cost of good intentions. Eichler HG; Abadie E; Raine JM; Salmonson T N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718 [No Abstract] [Full Text] [Related]
17. To market, to market. The nuts and bolts of prescription drug approval. Peterson AM Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443 [No Abstract] [Full Text] [Related]
18. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
19. Off-label drug use. Dooley AG Med Health R I; 2007 Feb; 90(2):63-5. PubMed ID: 17500258 [No Abstract] [Full Text] [Related]